Kardigan, Inc.

Nasdaq: KARD

Day 114 public/EMERGING/IPO Jun 18, 2026/Pharmaceutical Preparations

$14.67

▲ 0.47 (+3.31%)

LIVE

updated 17h ago

Intelligence Core

MONITORING

No new filings in 72 h · watching for the next event

Current missionDurability · Day 91–180

Determine whether the company is establishing durable public-market positioning.

Focus

Sustained fundamentalsOwnershipValuationRecurring catalysts

NEUTRALFORMING THESIS…Intelligence score DERIVED

/ 100

Confidence65%

CURRENT THESIS INTERPRETED

Kardigan, Inc. is an emerging clinical-stage pharmaceutical company public for 114 days with moderate technical momentum, strong institutional ownership signals via multiple Schedule 13D/13G filings, and fundamental characteristics typical of its sector including net losses backed by cash and positive equity.

Momentum

Price · since IPOLIVE

Yahoo · 79 pts

H $25.90L $13.49Last $14.67

Current ThesisINTERPRETEDLIVE

Why

+Institutional ownership indicated by 8 Schedule 13D/13G filings on file with the SEC
+Positive recent price momentum with a 1-day move of plus 3.31 percent to $14.67
+Active insider and regulatory reporting with 26 insider forms and multiple 8-K filings

Risks

−Clinical-stage sector risk profile resulting in fundamental risk score of 58
−Ongoing net losses reported in SEC XBRL filings
−Early stage of public lifecycle at 114 days post-IPO bucket

Catalysts

→Upcoming clinical or regulatory pipeline updates disclosed via 8-K filings
→Further institutional accumulation evidenced by ongoing Schedule 13D/13G disclosures

Current Thesis

Company Web Research · Official DomainVIEW ONLY

https://kardigan.bio

VIEW-ONLY

Visit

Capturing kardigan.bio…

Screenshot of Kardigan, Inc.'s official website

SNAPSHOT · live view blocked by site (X-Frame-Options: SAMEORIGIN)

Resolving official website…

Research EnvironmentLIVE

Research environment · $KARDSEC · market · news

22 evidence items|newest evidence 9d ago

Core activity · newest firstreal events · view-only

0s agoSCOREDERIVEDIntelligence score 75/100 recomputed from 5 rule-based signals.via Deterministic scoreDERIVED

0s agoSTATECore MONITORING · No new filings in 72 h · watching for the next event. Mission: Durability.via Intelligence Core

17h agoOBSERVATIONVERIFIEDLast price $14.67 · +3.31% on the day.via Finnhub quoteVERIFIED

Oct 1, 2026EVIDENCEVERIFIEDForm SCHEDULE 13D/A filed.via SEC EDGARVERIFIED Oct 1, 2026EVIDENCEVERIFIEDForm 3 filed · 3.via SEC EDGARVERIFIED Oct 1, 2026EVIDENCEVERIFIEDForm 4 filed · 4.via SEC EDGARVERIFIED 10d agoEVIDENCEKardigan Announces Appointment of Kristin Reinke to its Board of Directorsvia Yahoo · tier 3, cross-check Sep 30, 2026EVIDENCEVERIFIEDForm 8-K filed · 8-K.via SEC EDGARVERIFIED 27d agoEVIDENCEKardigan: Funded Precision Cardiology Offers More Than Pipeline Diversificationvia SeekingAlpha · tier 3, cross-check 37d agoEVIDENCEKardigan to Present at Two September Investor Conferencesvia Yahoo · tier 3, cross-check Aug 13, 2026EVIDENCEVERIFIEDForm SCHEDULE 13G filed.via SEC EDGARVERIFIED

Evidence · SEC filing timelineVERIFIED

Filed	Form	Document	Source
2026-10-01	4	4	SEC ↗
2026-10-01	3	3	SEC ↗
2026-10-01	SCHEDULE 13D/A	Kardigan, Inc.	SEC ↗
2026-09-30	8-K	8-K	SEC ↗
2026-08-13	SCHEDULE 13G	Kardigan, Inc.

VERIFIEDfrom a primary sourceDERIVEDcomputed by rulesINTERPRETEDreasoned from evidence

Assembled 0s ago · every panel labelled live or simulated · no fabricated metrics